TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05368649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Description: The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
Study: NCT04938336

Intervention type: BEHAVIORAL
Intervention: Delphi Procedure and interviews
Description: Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers

Intervention type: BEHAVIORAL
Intervention: Delphi Procedure and interviews
Description: Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
Study: NCT05759793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T (CAR-GPRC5D)
Description: CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation and cytokine secretion. The persistence of CAR-T is enhanced by 4-1BB costimulation signal.
Study: NCT06532305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE empowerment classes
Description: A three-month empowerment course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HOPE empowerment classes
Description: A three-month empowerment course.
Study: NCT05112705

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Proximal lower limb ultrasound
Description: Twice weekly proximal lower limb ultrasound
Study: NCT04923451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Trans-cranial direct current stimulation (tDCS)
Description: 5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Trans-cranial direct current stimulation (tDCS)
Description: 5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
Study: NCT05504525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca block
Description: Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
Study: NCT01089179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT05482334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim for Injection
Description: Recombinant human GM-CSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Bacteriostatic Saline
Study: NCT04311632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Standard of Care induction therapy in solid organ transplantation
Study: NCT05000762

Intervention type: DIETARY_SUPPLEMENT
Intervention: Zinc
Description: Zinc gluconate 30 mg/day orally
Study: NCT06319118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroergotine mesylate sustained-release tablets
Description: Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
Study: NCT06098040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flash glucose monitoring continuous
Description: Group 2 (FGM continuous): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion continuously for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: capillary blood test
Description: Group 1 (SMBG): will be asked to test capillary blood glucose as recommended by subjects' usual provider for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flash glucose monitoring intermittent
Description: Group 3 (FGM intermittent): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion 1 week off/2 weeks on for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
Study: NCT05926492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib plus chemotherapy
Description: Surufatinib: (1) for patients aged \> 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.
Study: NCT05952999

Intervention type: OTHER
Intervention: Digital Care Solution as supportive personalized care
Description: Patients will need to meet screening and inclusion criteria at time of enrollment. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.

Intervention type: OTHER
Intervention: Traditional Hospital Level Care
Description: Patients will be cared for in the inpatient setting for management of diseases that meet screening and inclusion criteria at time of enrollment for hospital at home. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
Study: NCT05317351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Intelligence Aided Colonoscopy (GI Genius™)
Description: Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy
Description: Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™).
Study: NCT06389461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4th Ventricular Compression Technique
Description: The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator joins hands in a cupping position, with the pads of the 1st fingers forming a triangle. The pads of the 1st fingers make contact with the spinous processes of the 2nd and 3rd cervical vertebrae. The thenar eminences make contact with the occipital squama, avoiding contact with the occipito-mastoid sutures during 5 minutes.~A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Therapy
Description: The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator places hands on the patient's shoulders during 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
Study: NCT05432089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: 24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Description: 24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
Study: NCT06140862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calf muscle strengthening and streching
Description: lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.

Intervention type: OTHER
Group type: OTHER
Intervention: calf muscle strengthening and streching
Description: lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
Study: NCT05147090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Identical in appearance to empagliflozin 10mg daily
Study: NCT05737199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 (pembrolizumab)
Description: MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
Study: NCT06014398

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic testing of Pituitary Function
Description: Pituitary Function Assessment:~Baseline assessment of pituitary function by measuring ACTH, cortisol, FSH, LH, oestrogen (in females), testosterone (in males), sex hormone binding globulin, thyroid function tests, prolactin and IGF-1\].~Dynamic testing of pituitary function:~* Patients will undergo dynamic testing of the ACTH and growth hormone axes using a glucagon stimulation test (GST).~* Patients whose GST identifies cortisol deficiency will undergo a short synacthen test to confirm adrenal insufficiency as the GST has a false positive rate of approximately 20% for ACTH deficiency.
Study: NCT06133062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: * 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.
Study: NCT06338137

Intervention type: DEVICE
Group type: OTHER
Intervention: Holmium Yag laser
Description: Use two laser energy low and high to reach the optimal setting for stone dusting

Intervention type: DEVICE
Group type: OTHER
Intervention: Holmium Yag laser
Description: Use two laser energy low and high to reach the optimal setting for stone dusting
Study: NCT05423743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Routine Care
Description: Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection
Description: Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having an abdominal infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
Study: NCT05181293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Gaming App for Nutrition Intervention
Description: A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
Study: NCT05905978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal donors predisposed by CXL
Description: Corneal donors predisposed by CXL and DALK procedure was conducted in patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal donors stored in corneal storage media
Description: Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
Study: NCT06098742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antareit
Description: A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antareit
Description: A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
Study: NCT05724511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIYAIRI 588
Description: In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
Study: NCT04892849

Intervention type: OTHER
Intervention: Conventional Therapy acc. to prevailing clincal approved schemes
Description: The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
Study: NCT05212870

Intervention type: OTHER
Intervention: assessment of cognitive level, pain catastrophe, physical activity level and quality of life
Description: assessment of cognitive level, pain catastrophe, physical activity level and quality of life

Intervention type: OTHER
Intervention: assessment of cognitive level, pain catastrophe, physical activity level and quality of life
Description: assessment of cognitive level, pain catastrophe, physical activity level and quality of life
Study: NCT04916691

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EPSB for rib fractures
Description: EPSB for rib fractures

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Standard of care weight-based optimal Ropivacaine dosing for ESPB
Study: NCT05133310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
Study: NCT06062342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FPI
Description: The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
Study: NCT04937465

Intervention type: OTHER
Intervention: No intervention done
Description: No intervention was done. This was an observational study.
Study: NCT06268756

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT04143464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kyphosis-specific exercise class and kyphosis-specific exercise videos
Description: The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos.
Study: NCT04846413

Intervention type: OTHER
Intervention: Speech task
Description: Speech task which consists of a sustained emission of the vowel /e/.
Study: NCT04963985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis Pill
Description: Oral
Study: NCT05284526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Description: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Description: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Description: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Study: NCT05294289

Intervention type: OTHER
Intervention: Alpelisib
Description: There is no treatment allocation. Patients administered alpelisib by prescription that involved in Novartis' alpelisib managed access program will be enrolled